Garden States - Cultivating Ethnobotanical Plant Knowledge


Purchase your Garden States early bird tickets here


Important Update:  As most of you will be aware, the global outbreak of coronavirus (COVID-19) and the recent Australian restrictions on mass gatherings have led to the cancellation of many planned events in the coming months.

In the interest of public health, EGA has moved the Garden States Botanical Symposium from the original date of Saturday, 9th of May to Sunday, 6th December 2020

This new date allows us to keep the same venue and event format, so it's the most logical move. It is our traditional outdoor symposium weekend, so it should be familiar to many of you in the community. We expect the program will also be much the same, but given the circumstances, some slight changes may be expected.

Any current ticket will be valid for the new date, and we encourage you to support us and still attend this exceptional day! However, if you cannot attend the new date, you can contact and arrange a full refund (less booking fees). If you require a refund please let us know as soon as possible.

We're immensely grateful for your support of our botanical initiative. Entheogenesis Australis is a volunteer-run charitable, educational organisation, and the sudden event move has had a financial impact, so if you like what we do and the projects we're producing, you can support us via the following link:


We have pulled together a richly diverse program from across Australia, New Zealand and beyond, including keynote presentations from internationally acclaimed artist Janet Laurence (AU), Dr Suresh Muthukumarasway (NZ) on microdosing studies, Dr Margaret Ross and Dr Martin Williams (AU) on Melbourne's St Vincent's Hospital psilocybin trial, Kirsty MacLeod (NZ) on ibogaine therapy, Monica Barratt (AU)  on trends in ethnobotanical plant data from the Global Drug Survey, and psychedelic critical thinker David Nickles (NZ/USA) discussing the latest underground research. They will be joined by a host of other botanically minded talent for a full day of programming over two spaces. Gather with us to expand your mind, body, community and garden.

Local speakers include, Communacacian, Jef Baker, Rachel Gagen, and Nick Sun.

There will be two Panels on the day: Psychedelics and ethics, and Botanical art panel.

Workshops include: Darklight & Caine Barlow will be running two workshops - a basics and then an advanced workshop, Amanda Morglund will demonstrate the principles of mycroremediation, Rodni Chisar will be doing a cactus workshop, and Beau Meister a horticulture workshop.  Beau Meister will also be leading a mushroom foray on the 10th of May, details closer to the date.

Other people on the day will include Meredith Drinkell and Nick Wallis.

As our last few EGA symposiums and events have sold out well in advance and tickets are strictly limited, we highly recommend booking your Garden States tickets early. Early Bird tickets are available until November 9th if they are not sold out before. We also offer discounted tickets for First Nations people and mothers/sole parents, as well as concession & hardship tickets.


You can find the Garden States Facebook event group here.


Dr Margaret Ross is a consultant clinical psychologist and the clinical lead in Australia’s first ever psychedelic clinical trial. The trial will be based at St Vincent’s Hospital in Melbourne and will investigate the ability of psilocybin-assisted therapy to alleviate anxiety and depression in terminally ill patients.

The St Vincent’s clinical trial will see palliative care patients given one to two doses of psilocybin and psychotherapy in a treatment protocol shown in overseas trials to produce rapid and dramatic improvements in depression and anxiety, and provide an altered outlook on their situation approaching death. Alongside psychotherapy and guidance, the psychedelic medicines are hoped to give terminally ill patients a new perspective on their lives, and to reduce the fear and depression which can often take over their final months.

Margaret will talk about the study's progress, its history, aims, and practical workings, whilst addressing the rationale for how psilocybin works to alleviate anxiety and depression.



Dr Alison Pouliot is an ecologist, environmental photographer and honorary fellow at the Australian National University. Her research spans both northern and southern hemispheres where she is actively involved in fungal conservation and ethnomycology, conducting over 400 fungus workshops and forays over the last two decades.

Alison’s recent book, The Allure of Fungi (CSIRO Publishing) explores the natural and cultural curiosities of the fungal realm. Her new book (co-authored with mycologist Tom May) is the first field guide to edible fungi in Australia will be published later this year. More information is available at


Janet Laurence is a leading Sydney-based artist who exhibits nationally and internationally. Her practice examines our physical, cultural and conflicting relationship to the natural world. She creates immersive environments that navigate the interconnections between organic elements and systems of nature.

Within the recognised threat to so much of the life world, Janet explores what it might mean to heal the natural environment, fusing this with a sense of communal loss and search for connection with powerful life-forces. Her work is included in museum, university, corporate and private collections as well as within architectural and landscaped public places.


Dr Suresh Muthukumarasway is currently an Associate Professor in psychopharmacology at The University of Auckland.

Suresh started studying psychedelic drugs in 2011, collaborating with Professor David Nutt and Dr Robin Carhart-Harris, investigating the electrophysiology of psilocybin. Since then he has been involved in neuroscience studies of LSD, ketamine, DMT and ayahuasca. His research group is soon to start the first placebo controlled study of LSD microdosing, where participants will be allowed to take LSD at home on prescription.


Kirsty MacLeod is a counsellor and addictions practitioner from Dunedin, New Zealand.

She began training as an ibogaine provider after her own transformative ibogaine experience in 2012, and has since provided treatments for addiction, alongside her mentor, Tanea Paterson.

Kirsty has a particular interest in transformative psychedelic experiences and states of consciousness. She is passionate about the relationship between these experiences and creating lasting change. Kirsty is a proponent of post-treatment therapy and proper integration of the experience.

Currently working in the family violence sector, Kirsty is studying psychodrama and runs men's and women's therapy groups, as well as providing individual and relationship counselling.

Kirsty is looking to the future of ibogaine therapy in NZ and the challenges of attempting this as a mainstream treatment for addiction.


Martin Williams, PhD, is a research fellow in Medicinal Chemistry at the Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne. He is founding and current President of the DGR-registered health-promotion charity, Psychedelic Research in Science & Medicine (PRISM), founding and current Vice-President of the botanical/education charity, Entheogenesis Australis (EGA), Scientific Officer with the charity, Mind Medicine Australia, and co-lead investigator of the upcoming Melbourne psilocybin trials at St Vincent’s Hospital.

Through PRISM, Martin and his colleagues have been advocating since 2011 for mental health research using psychedelic compounds in Australia, and in doing so, have established connections with researchers in the USA, Canada, the Czech Republic, Germany, the Netherlands, New Zealand and the United Kingdom. In the course of planning and seeking approvals for two clinical trials, one of MDMA-assisted psychotherapy for the treatment of PTSD and the other of psilocybin-assisted psychotherapy for the treatment of anxiety and depression associated with terminal illness, Martin has become familiar with the Australian regulatory and research governance landscape.

Martin and the Palliative Care team at St Vincent’s Hospital, Melbourne, recently achieved the requisite Human Research Ethics and state and federal government approvals for their proposed Phase 2 psilocybin trial, which began in late January 2020. He is currently working with another interdisciplinary research group on plans for a clinical trial of psilocybin-assisted psychotherapy for treatment-resistant depression.


Monica Barratt is a Vice-Chancellor's Senior Research Fellow in the Social and Global Studies Centre at RMIT University. She is currently undertaking a four-year program of research investigating psychoactive drug use in digital society, with topics of interest including digital drug trading, digitally enabled communities, legislative responses to new or novel substances, translation of police data into public health alerts, drug checking and festival harm reduction, drug checking in the community, and microdosing. Monica has published over 70 academic research papers and attracted over $4M competitive funding in her almost 20-year career. She is the Australian lead for the Global Drug Survey and serves as an Editor for leading journals in the drugs field: International Journal of Drug Policy and Drug and Alcohol Review. Monica also volunteers at, a global drug harm reduction community recently celebrating 20 years, and for The Loop Australia, a not-for-profit organisation started in 2018 with the goal of conducting drug checking interventions both at festivals and in the community. Monica has attended and contributed to EGA since the mid 2000s, and she continues to advocate for recognition of the benefits and pleasures of psychoactive substance use in context with known risks, many of which arise from prohibition regimes themselves.


David Nickles is an underground researcher and harm reduction advocate who serves as an editor for Psymposia Media, co-host of the Plus Three podcast, and intermittent moderator of the DMT-Nexus community.

David has presented social critiques and commentary on psychedelic culture and radical politics, as well as novel phytochemical data, at venues around the world. His work focuses on the social and cultural implications of psychoactive substances, utilising critical theory and structural analysis to examine the intersections of drugs and society. He is a vocal opponent of psychedelic commodification and blows glass in an idealistic attempt to avoid monetising his psychedelic work.


Entheogenesis Australis is a charitable, educational organisation established in 2004; we provide opportunities for critical thinking and knowledge sharing on ethnobotanical plants, fungi, nature and sustainability.

Through our conferences and workshops, we aim to celebrate the culture, art, politics and community around medicine plants in the hope to better wellbeing for humankind and the planet.